ClassOne Insight

ClassOne Insight

  • 9650 Strickland Road Suite 103-340
  • Raleigh, North Carolina
  • 27615

Description

Gregg Kasten leads the design and development of ClassOne Insight?s technology and InfoStream service. Gregg?s career has been focused on building products and deploying solutions that meet customers? needs to improve operational efficiency and optimize financial performance.

In addition to providing the InfoStream service, ClassOne Insight consults with companies on operational efficiency and business performance, focusing on improving a company?s use of information to understand and optimize its results. ClassOne Insight?s leaders have extensive experience in both operating and consulting roles, and have worked with executives and operating managers in diverse functional areas across multiple industries.

Then we augment that data to give you unparalleled insight into your business. We provide this insight in two ways: we categorize your data according to business dimensions that are already present in your data, and we also augment it with our Knowledge Tree ™ Engine to "flesh out" categories that are not explicitly obvious in your data. For example, our Knowledge Tree Engine can group your data by non-municipal geographic regions (e.g. U.S. Government Metropolitan Statistical Areas) that are not explicitly present in your data.

John McGrory serves as ClassOne Insight?s Chief Executive Officer, and leads the company?s overall strategy and execution. Prior to ClassOne, John led three other enterprise software and service companies, all of which were focused on both achieving dramatic improvements in customers? business performance and delivering high levels of customer service.

ClassOne Insight works with traditional, biotech and specialty pharmaceutical manufacturers, ranging from companies serving large patient populations with traditional commercial business practices, companies with specialized distribution and product handling needs as well as manufacturers serving specialized or limited patient populations (including orphan and ultra orphan drugs).

Companies nearby